<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang</h1>
  <ul>
<li>08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.</li>
<li>NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025.</li>
<li>NXC-201 is being evaluated in the U.S.</li>
<li>Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and c</li>
<li>multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design.</li>
<li>Dr.</li>
<li>CEO Dr.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/immix-biopharma-announces-strategic-investment-200500034.html">Source</a> · 2025-09-08T20:05:00+00:00</p>
</body>
</html>